Since NLRC5 expression is required for efficient cytotoxic CD8+ T cell responses, we hypothesized that NLRC5 may be important for mediating the clinical benefits of cancer patients treated with checkpoint inhibitors24,37. The gene discussed is CD8A; the disease is cancer.